JPWO2023133577A5 - - Google Patents
Info
- Publication number
- JPWO2023133577A5 JPWO2023133577A5 JP2024541033A JP2024541033A JPWO2023133577A5 JP WO2023133577 A5 JPWO2023133577 A5 JP WO2023133577A5 JP 2024541033 A JP2024541033 A JP 2024541033A JP 2024541033 A JP2024541033 A JP 2024541033A JP WO2023133577 A5 JPWO2023133577 A5 JP WO2023133577A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- months
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298133P | 2022-01-10 | 2022-01-10 | |
| US63/298,133 | 2022-01-10 | ||
| US202263307911P | 2022-02-08 | 2022-02-08 | |
| US63/307,911 | 2022-02-08 | ||
| US202263327986P | 2022-04-06 | 2022-04-06 | |
| US63/327,986 | 2022-04-06 | ||
| PCT/US2023/060358 WO2023133577A1 (en) | 2022-01-10 | 2023-01-10 | Methods of treating or reducing risk of transplant rejection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502095A JP2025502095A (ja) | 2025-01-24 |
| JPWO2023133577A5 true JPWO2023133577A5 (https=) | 2026-01-20 |
| JP2025502095A5 JP2025502095A5 (https=) | 2026-01-20 |
Family
ID=87074361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541033A Pending JP2025502095A (ja) | 2022-01-10 | 2023-01-10 | 移植拒絶反応のリスクを処置または低減する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230287132A1 (https=) |
| EP (1) | EP4463182A1 (https=) |
| JP (1) | JP2025502095A (https=) |
| KR (1) | KR20240131437A (https=) |
| AU (1) | AU2023205152A1 (https=) |
| CA (1) | CA3242941A1 (https=) |
| MX (1) | MX2024008562A (https=) |
| WO (1) | WO2023133577A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040932A1 (en) | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2970493T (pt) * | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| WO2017040932A1 (en) * | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
-
2023
- 2023-01-10 AU AU2023205152A patent/AU2023205152A1/en active Pending
- 2023-01-10 WO PCT/US2023/060358 patent/WO2023133577A1/en not_active Ceased
- 2023-01-10 KR KR1020247026684A patent/KR20240131437A/ko active Pending
- 2023-01-10 US US18/152,519 patent/US20230287132A1/en active Pending
- 2023-01-10 CA CA3242941A patent/CA3242941A1/en active Pending
- 2023-01-10 JP JP2024541033A patent/JP2025502095A/ja active Pending
- 2023-01-10 EP EP23737837.7A patent/EP4463182A1/en active Pending
-
2024
- 2024-07-08 MX MX2024008562A patent/MX2024008562A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202323296A (zh) | 組合療法 | |
| CA2186269C (en) | Wound healing | |
| JP2002500648A (ja) | 反適応性の免疫応答、特に移植片拒絶を防ぐためのｃｄ４０：ｃｄ１５４結合妨害剤の使用 | |
| JP2019530728A5 (https=) | ||
| US4731244A (en) | Monoclonal antibody therapy | |
| JPS6256440A (ja) | 不要細胞の分解あるいは阻止物質からなる治療剤 | |
| Myburgh et al. | Total lymphoid irradiation in renal transplantation | |
| JPWO2023133577A5 (https=) | ||
| Egan et al. | Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab | |
| CN116783216A (zh) | 用于诱导耐受性的方法和组合物 | |
| AU2007207074B2 (en) | Isolated organ perfusion combination therapy of cancer | |
| JPWO2020092549A5 (https=) | ||
| JP2023551193A (ja) | 抗体関連型拒絶反応を処置するための方法 | |
| JP2002530354A (ja) | 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子 | |
| CA2100876A1 (en) | Anti-growth factor antibodies in the treatment of vascular stenosis | |
| US20120251496A1 (en) | Ezatiostat for treating multiple myeloma | |
| CN112773802B (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 | |
| Yasuda et al. | The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease | |
| JPWO2022058445A5 (https=) | ||
| JPWO2020178638A5 (https=) | ||
| Moon | Overcoming high pre-transplant isoagglutinin titers using high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab without splenectomy in ABO-incompatible living donor liver transplantation: a case report | |
| HK40124218A (zh) | 延长移植物和受体存活期的组合物和方法 | |
| JPWO2020102375A5 (https=) | ||
| KR20250120401A (ko) | 이식물 및 수혜자의 생존을 연장하기 위한 조성물 및 방법 |